Eris Lifesciences Limited has informed the Exchange regarding allotment of 2306372 securities pursuant to Preferential Issue at its meeting held on January 16, 2026
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences has completed the allotment of 23,06,372 securities to specific investors under a Preferential Issue. The allotment was approved at a board meeting held on January 16, 2026, and the company has informed the NSE of the completion. Preferential Issues are private placements made to select investors at a price determined by the board, not broad-market offerings like IPOs or QIPs. The company has not disclosed the issue price or the names of the allottees in this filing.
Existing shareholders may see dilution of their holding as new securities are issued to private investors. Short-term stock reaction will depend on the issue price relative to current market price and the profile of the allottees — further clarity is needed from the company on pricing and use of funds.